Ocular Therapeutix, Inc.
General ticker "OCUL" information:
- Sector: Health Care
- Industry: Pharmaceuticals
- Capitalization: $1.6B (TTM average)
Ocular Therapeutix, Inc. follows the US Stock Market performance with the rate: 59.4%.
Estimated limits based on current volatility of 4.1%: low 11.22$, high 12.19$
Factors to consider:
- Total employees count: 274 (+2.6%) as of 2024
- Top business risk factors: Regulatory and compliance, Intellectual property risks, Cybersecurity threats, Geopolitical risks, Labor/talent shortage/retention
- Price in estimated range
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [5.26$, 13.54$]
- 2025-12-31 to 2026-12-31 estimated range: [3.75$, 10.23$]
Financial Metrics affecting the OCUL estimates:
- Negative: with PPE of -8.2 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -10.06 <= 0.33
- Negative: negative Industry operating cash flow (median)
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Interest expense per share per price, % of 1.01 <= 3.41
- Negative: Industry earnings per price (median), % of -16.34 <= 0
Short-term OCUL quotes
Long-term OCUL plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $51.49MM | $58.44MM | $63.72MM |
| Operating Expenses | $130.15MM | $140.82MM | $235.50MM |
| Operating Income | $-78.65MM | $-82.38MM | $-171.78MM |
| Non-Operating Income | $7.62MM | $1.65MM | $-21.73MM |
| Interest Expense | $7.02MM | $11.34MM | $13.58MM |
| R&D Expense | $53.46MM | $61.05MM | $127.64MM |
| Income(Loss) | $-71.04MM | $-80.74MM | $-193.51MM |
| Profit(Loss)* | $-71.04MM | $-80.74MM | $-193.51MM |
| Stockholders Equity | $35.38MM | $91.13MM | $315.34MM |
| Inventory | $1.97MM | $2.31MM | $3.04MM |
| Assets | $149.29MM | $252.06MM | $457.94MM |
| Operating Cash Flow | $-59.60MM | $-70.23MM | $-134.68MM |
| Capital expenditure | $3.71MM | $6.09MM | $1.29MM |
| Investing Cash Flow | $-3.71MM | $-6.09MM | $-1.29MM |
| Financing Cash Flow | $1.45MM | $169.83MM | $332.11MM |
| Earnings Per Share** | $-0.92 | $-1.01 | $-1.22 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.